Top in endocrinology: SGLT2 inhibitors, tirzepatide for type 2 diabetes
Click Here to Manage Email Alerts
Two experts debated whether SGLT2 inhibitors should be used as a first-line therapy for patients with type 2 diabetes. This point-counter point was the top story in endocrinology last week.
Another top story included new data on tirzepatide (Eli Lilly). According to the manufacturer, once-weekly tirzepatide led to greater reductions in HbA1c and body weight compared with titrated insulin glargine (Lantus, Sanofi) among adults with type 2 diabetes and a history of cardiovascular events.
Read these and more top stories in endocrinology below:
Should SGLT2 inhibitors be first-line therapy for type 2 diabetes?
George Grunberger, MD, FACP, MACE, chairman of the Grunberger Diabetes Institute in Bloomfield Hills, Michigan, and Daniel Einhorn, MD, FACE, FACP, a clinical endocrinologist with Diabetes and Endocrine Associates and medical director of Scripps Whittier Diabetes Institute in La Jolla, California, discuss the role of SGLT2 inhibitors in type 2 diabetes. Read more.
SURPASS-4: Tirzepatide reduces HbA1c, body weight in type 2 diabetes
The GIP/GLP-1 receptor agonist tirzepatide significantly reduced HbA1c and body weight compared with insulin glargine for adults with type 2 diabetes at high cardiovascular risk, according to new data from the SURPASS trial program. Read more.
Obesity increases likelihood of peak COVID-19 antibody levels after infection
Adults with obesity or severe obesity who test positive for COVID-19 are more likely to have peak antibody titer levels compared with those without obesity, according to a study published in Obesity. Read more.
Diabetes drugs now ‘pillars of care’ for heart failure
Heart failure and type 2 diabetes are exquisitely intertwined. Their shared pathophysiology can accelerate debilitating outcomes for patients that clinicians struggle to prevent and treat. Read more.
Hemithyroidectomy provides lower risks, similar benefits as total thyroidectomy for DTC
Adults with differentiated thyroid cancer who underwent hemithyroidectomy had lower risks for surgical complications compared with those who had total or near-total thyroidectomy, according to study data. Read more.